Qilu Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 1992-08-21

Employees: 10K

Market Cap: -

Website: http://www.qilu-pharma.com

Clinical Trials

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

Phase 1

Conditions: COVID-19

Interventions: Drug: QLS1128 C-Dose 1~3 and Ritonavir
Drug: QLS1128 D-Dose 1 and Ritonavir
Drug: QLS1128 A-Dose 1~5 and Ritonavir

First Posted Date: 2022-07-14

Last Posted Date: 2022-07-14

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 86

Registration Number: NCT05458076

Locations: 🇨🇳
Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 3

Recruiting

Conditions: METASTATIC CERVICAL CANCER

Interventions: Drug: Placebo
Drug: QL1706
Drug: Paclitaxel injection
Drug: Cisplatin/Carboplatin

First Posted Date: 2022-07-07

Last Posted Date: 2022-11-30

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 498

Registration Number: NCT05446883

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China

A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Phase 3

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Aflibercept

First Posted Date: 2022-04-25

Last Posted Date: 2022-04-25

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 366

Registration Number: NCT05345236

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: QL1706

First Posted Date: 2022-04-14

Last Posted Date: 2023-11-24

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT05329025

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: QL1706
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2022-04-04

Last Posted Date: 2023-05-18

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05309629

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study of QLS31905 in Patients With Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumors

Interventions: Drug: QLS31905

First Posted Date: 2022-03-14

Last Posted Date: 2022-03-14

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 104

Registration Number: NCT05278832

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Phase 1

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: QL1706 Plus Lenvatinib

First Posted Date: 2022-03-02

Last Posted Date: 2022-03-02

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT05262413

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3

Conditions: Multiple Myeloma
Recurrent or Refractory

Interventions: Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2022-02-11

Last Posted Date: 2022-02-11

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 85

Registration Number: NCT05236621

Locations: 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 20 locations

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: QL1706

First Posted Date: 2022-01-05

Last Posted Date: 2022-07-29

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT05179317

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, Shangdong, China
🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China

A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: QL1706 injection

First Posted Date: 2021-12-29

Last Posted Date: 2023-04-07

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 419

Registration Number: NCT05171790

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy